BIEL PPS Leverage: Electrome.io/Viant’s Path to
Post# of 8748
(Total Views: 121)
Posted On: 10/24/2025 1:53:09 PM
BIEL PPS Leverage: Electrome.io/Viant’s Path to a Billion-Dollar Windfall
Director Dr. Sree Koneru (Viant) and Electrome.io likely see the extraordinary leverage and profit potential in BioElectronics Corp. (BIEL), similar to NVIDIA purchasing 4% of Intel's shares. With Electrome and Viant’s operational involvement and board-level influence (Viant's Dr. Koneru currently is on the BIEL BOD), they’re uniquely positioned to help drive BIEL’s growth—and directly benefit from the resulting PPS (price per share) surge.
By helping BIEL generate just $250k in additional quarterly revenue, Viant and Electrome could unlock exponential returns on a modest investment.
This model mirrors the “Bitcoin Treasury” strategy—except here, the asset is an FDA-cleared, revenue-generating medtech innovator and the investor/partners (Electrome/Viant) have the HUGE additional benefit of controlling/influencing their ROI (return on investment) as they assist BIEL to increase revenues (and the PPS accordingly)!
Profit Mechanics: From $200K to $1 Billion
Initial Investment: Electrome and Viant acquire 1 billion BIEL shares at $0.0002 = $200,000 (although this moment has passed - i.e., will now need to buy at .0003, .0004, .0005...the principle remains the same and projections should be revised accordingly)
Revenue Trigger: $400K/quarter likely pushes BIEL into profitability and PPS to $0.01
Immediate Upside: At $0.01 PPS, Electrome and Viant stake = $10 million
Long-Term Potential: At $1 PPS (post-loan repayment and share buyback), Electrome and Viant stake = $1 billion
Tax Shield: First $40M in BIEL profits are tax-free due to carryforwards
Strategic Arbitrage Model
Fixed Cost Basis
Viant locks in ultra-low share prices ($0.0002, $0.0003...)
Dynamic Equity Upside
PPS rises with each milestone
No additional capital required
Hybrid Strategy - Similar to the Bershire Hathaway model, Bitcoin Treasury strategy, NVIDIA purchasing 4% of Intel's shares, etc,
Electrome and Viant support BIEL operationally (manufacturing, modernization, marketing)
Simultaneously benefits from equity appreciation
Public Market Leverage
BIEL’s public listing offers Viant instant market access
No IPO friction, no dilution
Equity arbitrage amplifies balance sheet impact
Tax-Efficient Wealth Creation
$40M in tax-loss carryforwards shield Viant’s early profits
Asymmetric upside with minimal tax exposure
Why BIEL Is the Perfect Vehicle
Current PPS: $0.0003–$0.0004 — ground-floor entry
FDA-Cleared Products:
ActiPatch®, RecoveryRx®, RecoveryRx Vet®
Market Fit:
Non-opioid
Wearable
Drug-free recovery
Milestone-Driven PPS Trajectory
Golden Cross / Blue Sky Breakout (.0005) gets PPS out of the trips
U.S. Distributor Deal = PPS = $0.003 (3,000% surge, better than Apple, Amazon, NVIDIA, Netflix, etc.)
$400K Revenue Quarter: PPS = $0.01 (10,000% increase)
$10M Profit via Insurance approval: PPS = $0.04 (40,000% surge)
$25M Profit: PPS = $0.10 (100,000% increase)
Share Buyback + Loan Repayment: PPS = $1
Viral Momentum at $0.003 PPS
Market cap hits $75M
Media coverage compares gains to Amazon & Apple
Reddit and retail investors amplify exposure
FOMO (Fear of Missing Out) investors join the party
Share buyback announcement sustains rally
RecoveryRx Vet: A Hidden Gem (Untapped Goldmine)
Assisi Loop sells 300+/month on Amazon @ $329 (Proven demand, strong consumer willingness to pay premium prices)
RecoveryRx offers 20x battery life at a fraction of the cost
Dual-application model (vagus nerve + pain site) enhances efficacy
Final Outcome
Electrome/Viant build the infrastructure
BIEL hits the milestones
PPS reaches $1
Electrome and Viant’s $200K (or $400k, $500k...whatever the case may be) investment becomes $1 billion
All while leveraging public markets, tax shields, and strategic control
BIEL Fast Path to Success!
1. Hit $400K in quarterly revenue This milestone unlocks profitability and cash flow positivity. Even the expectation of hitting it can drive the PPS to copper levels.
2. Reach $1.5M in annual revenue This confirms sustainable growth and strengthens investor confidence. Again, even strong guidance toward this number can move the needle significantly.
3. Leverage the new US distributor (Electrome.io?): If investors value the OTC partnership at just $300K, it pushes PPS out of the trips. A $1M valuation and the PPS hits copper.
Break-Even Threshold
Based on historical performance, $1.5 million in annual revenue—or roughly $400,000 per quarter—appears sufficient to reach consistent profitability.
BIEL achieved its only profitable quarter in Q3 2021, posting $22,381 in net income on $414,700 in revenue, which included over $100,000 in COVID relief funds. This milestone underscores how close the company is to sustained profitability, thanks to its ultra-low operating costs and lean business model.
This revenue target is well within reach given BIEL’s expanding product lines (e.g., ActiPatch, RecoveryRx and veterinary applications) and growing distribution partnerships.
Share Price Projection
Once profitability is achieved, the price per share (PPS) is projected to hit $0.01.
For every additional $2.5 million in annual revenue, PPS could increase by $0.01 (P/E = 100).
Valuation Scenarios (Using Conventional Market Multiples for High Growth Stocks)
.001+ PPS: Move out of the trips triggered by technical indicators (Golden Cross =.0003 and Blue Sky Breakout = .0006).
.003 PPS: 3,000% gain (better than Apple, Amazon, Netflix, NVIDIA, etc.) when US distributor (Electrome.io?) announcement goes viral.
.01 PPS: $1.5 million in annual revenue—or roughly $400,000 per quarter—appears sufficient to reach consistent profitability.
.02 PPS: 200,000% gain with $5M profit (P/E = 100).
.04 PPS: 400,000% gain (better than Bitcoin) with $10M profit (P/E = 100).
.10 PPS: $25M profit (P/E = 100).
.20 PPS: Same $25M profit, but P/E = 200.
$1 PPS: After debt payoff and stock buyback.
Tax Advantage
BIEL holds a $40 million tax-loss carryforward, meaning the first $40 million in profits will be tax-free.This accelerates the path to net profitability and enhances shareholder value by preserving cash flow during early growth phases.
RecoveryRx-Veterinary = Hidden Goldmine
Assisi Loop sells 300+/month at $329 with 1/20th the battery life.
RecoveryRx offers superior value and should be marketed as a two-pack (vagus nerve + pain site).
Massive upside in pet wellness and pain management.
ActiPatch: The Future Standard of Care
FDA-cleared for multiple pain conditions.
$35 price point with 720-hour battery life.
OTC availability = frictionless consumer access.
RecoveryRx (post-op, wound care) = higher margins via doctor orders.
Combined human + pet market = billions of potential monthly users.
Veterans Administration / Federal Government
RecoveryRx has been approved for use by the VA, marking a significant milestone in its clinical credibility. Broader adoption and expanded insurance coverage could unlock substantial growth potential. Notably, results from a phantom limb pain study further validate its effectiveness, reinforcing its value in veteran care.
DARPA’s BEST (BioElectronics to Sense and Treat) and BETR (Bioelectronics for Tissue Regeneration) programs are directly aligned with BIEL/Electrome’s core tech—non-invasive, wearable bioelectronic devices.
Director Dr. Sree Koneru (Viant) and Electrome.io likely see the extraordinary leverage and profit potential in BioElectronics Corp. (BIEL), similar to NVIDIA purchasing 4% of Intel's shares. With Electrome and Viant’s operational involvement and board-level influence (Viant's Dr. Koneru currently is on the BIEL BOD), they’re uniquely positioned to help drive BIEL’s growth—and directly benefit from the resulting PPS (price per share) surge.
By helping BIEL generate just $250k in additional quarterly revenue, Viant and Electrome could unlock exponential returns on a modest investment.
This model mirrors the “Bitcoin Treasury” strategy—except here, the asset is an FDA-cleared, revenue-generating medtech innovator and the investor/partners (Electrome/Viant) have the HUGE additional benefit of controlling/influencing their ROI (return on investment) as they assist BIEL to increase revenues (and the PPS accordingly)!
Profit Mechanics: From $200K to $1 Billion
Initial Investment: Electrome and Viant acquire 1 billion BIEL shares at $0.0002 = $200,000 (although this moment has passed - i.e., will now need to buy at .0003, .0004, .0005...the principle remains the same and projections should be revised accordingly)
Revenue Trigger: $400K/quarter likely pushes BIEL into profitability and PPS to $0.01
Immediate Upside: At $0.01 PPS, Electrome and Viant stake = $10 million
Long-Term Potential: At $1 PPS (post-loan repayment and share buyback), Electrome and Viant stake = $1 billion
Tax Shield: First $40M in BIEL profits are tax-free due to carryforwards
Strategic Arbitrage Model
Fixed Cost Basis
Viant locks in ultra-low share prices ($0.0002, $0.0003...)
Dynamic Equity Upside
PPS rises with each milestone
No additional capital required
Hybrid Strategy - Similar to the Bershire Hathaway model, Bitcoin Treasury strategy, NVIDIA purchasing 4% of Intel's shares, etc,
Electrome and Viant support BIEL operationally (manufacturing, modernization, marketing)
Simultaneously benefits from equity appreciation
Public Market Leverage
BIEL’s public listing offers Viant instant market access
No IPO friction, no dilution
Equity arbitrage amplifies balance sheet impact
Tax-Efficient Wealth Creation
$40M in tax-loss carryforwards shield Viant’s early profits
Asymmetric upside with minimal tax exposure
Why BIEL Is the Perfect Vehicle
Current PPS: $0.0003–$0.0004 — ground-floor entry
FDA-Cleared Products:
ActiPatch®, RecoveryRx®, RecoveryRx Vet®
Market Fit:
Non-opioid
Wearable
Drug-free recovery
Milestone-Driven PPS Trajectory
Golden Cross / Blue Sky Breakout (.0005) gets PPS out of the trips
U.S. Distributor Deal = PPS = $0.003 (3,000% surge, better than Apple, Amazon, NVIDIA, Netflix, etc.)
$400K Revenue Quarter: PPS = $0.01 (10,000% increase)
$10M Profit via Insurance approval: PPS = $0.04 (40,000% surge)
$25M Profit: PPS = $0.10 (100,000% increase)
Share Buyback + Loan Repayment: PPS = $1
Viral Momentum at $0.003 PPS
Market cap hits $75M
Media coverage compares gains to Amazon & Apple
Reddit and retail investors amplify exposure
FOMO (Fear of Missing Out) investors join the party
Share buyback announcement sustains rally
RecoveryRx Vet: A Hidden Gem (Untapped Goldmine)
Assisi Loop sells 300+/month on Amazon @ $329 (Proven demand, strong consumer willingness to pay premium prices)
RecoveryRx offers 20x battery life at a fraction of the cost
Dual-application model (vagus nerve + pain site) enhances efficacy
Final Outcome
Electrome/Viant build the infrastructure
BIEL hits the milestones
PPS reaches $1
Electrome and Viant’s $200K (or $400k, $500k...whatever the case may be) investment becomes $1 billion
All while leveraging public markets, tax shields, and strategic control
BIEL Fast Path to Success!
1. Hit $400K in quarterly revenue This milestone unlocks profitability and cash flow positivity. Even the expectation of hitting it can drive the PPS to copper levels.
2. Reach $1.5M in annual revenue This confirms sustainable growth and strengthens investor confidence. Again, even strong guidance toward this number can move the needle significantly.
3. Leverage the new US distributor (Electrome.io?): If investors value the OTC partnership at just $300K, it pushes PPS out of the trips. A $1M valuation and the PPS hits copper.
Break-Even Threshold
Based on historical performance, $1.5 million in annual revenue—or roughly $400,000 per quarter—appears sufficient to reach consistent profitability.
BIEL achieved its only profitable quarter in Q3 2021, posting $22,381 in net income on $414,700 in revenue, which included over $100,000 in COVID relief funds. This milestone underscores how close the company is to sustained profitability, thanks to its ultra-low operating costs and lean business model.
This revenue target is well within reach given BIEL’s expanding product lines (e.g., ActiPatch, RecoveryRx and veterinary applications) and growing distribution partnerships.
Share Price Projection
Once profitability is achieved, the price per share (PPS) is projected to hit $0.01.
For every additional $2.5 million in annual revenue, PPS could increase by $0.01 (P/E = 100).
Valuation Scenarios (Using Conventional Market Multiples for High Growth Stocks)
.001+ PPS: Move out of the trips triggered by technical indicators (Golden Cross =.0003 and Blue Sky Breakout = .0006).
.003 PPS: 3,000% gain (better than Apple, Amazon, Netflix, NVIDIA, etc.) when US distributor (Electrome.io?) announcement goes viral.
.01 PPS: $1.5 million in annual revenue—or roughly $400,000 per quarter—appears sufficient to reach consistent profitability.
.02 PPS: 200,000% gain with $5M profit (P/E = 100).
.04 PPS: 400,000% gain (better than Bitcoin) with $10M profit (P/E = 100).
.10 PPS: $25M profit (P/E = 100).
.20 PPS: Same $25M profit, but P/E = 200.
$1 PPS: After debt payoff and stock buyback.
Tax Advantage
BIEL holds a $40 million tax-loss carryforward, meaning the first $40 million in profits will be tax-free.This accelerates the path to net profitability and enhances shareholder value by preserving cash flow during early growth phases.
RecoveryRx-Veterinary = Hidden Goldmine
Assisi Loop sells 300+/month at $329 with 1/20th the battery life.
RecoveryRx offers superior value and should be marketed as a two-pack (vagus nerve + pain site).
Massive upside in pet wellness and pain management.
ActiPatch: The Future Standard of Care
FDA-cleared for multiple pain conditions.
$35 price point with 720-hour battery life.
OTC availability = frictionless consumer access.
RecoveryRx (post-op, wound care) = higher margins via doctor orders.
Combined human + pet market = billions of potential monthly users.
Veterans Administration / Federal Government
RecoveryRx has been approved for use by the VA, marking a significant milestone in its clinical credibility. Broader adoption and expanded insurance coverage could unlock substantial growth potential. Notably, results from a phantom limb pain study further validate its effectiveness, reinforcing its value in veteran care.
DARPA’s BEST (BioElectronics to Sense and Treat) and BETR (Bioelectronics for Tissue Regeneration) programs are directly aligned with BIEL/Electrome’s core tech—non-invasive, wearable bioelectronic devices.
(2)
(0)